18
Participants
Start Date
September 1, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
SBRT + atezolizumab and bevacizumab
"Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT.~Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks.~Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks."
RECRUITING
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Abramson Cancer Center at Penn Medicine
OTHER